Literature DB >> 11771755

Expression patterns of chaperone proteins in cerebral cortex of the fetus with Down syndrome: dysregulation of T-complex protein 1.

B C Yoo1, M Fountoulakis, M Dierssen, G Lubec.   

Abstract

Chaperone proteins reduce stress-induced denaturation and aggregation of intracellular proteins and exert protective actions by interfering with the stress-induced apoptotic pathway in the neuronal cells. Although many studies have focused on the critical role of chaperones in protein folding and their relevance in protein conformational diseases such as Alzheimer's disease (AD) and prion disease, limited information is available on their expression pattern in AD-related disease, Down Syndrome (DS). In a previous study, we reported differentially expressed molecular chaperone proteins in the brains of adult DS patients. This report demonstrated the relevance of the aberrant expression patterns to biochemical and neuropathological abnormalities in adult DS brain. To investigate whether this aberrant expression patterns already exist in second trimester DS brain, we performed two-dimensional polyacrylamide gel electrophoresis (2-DE) and matrix-associated laser desorption ionization mass spectroscopy (MALDI-MS) using fetal DS brain. We unambiguously identified and quantified twelve heat shock proteins (HSPs), three glucose regulated proteins (GRPs) and eight T-complex 1 (TCP-1) subunits. Unlike in adult brain with DS, these studies provide evidence for the normal response of most molecular chaperone proteins at the given time point of DS brain development. However, chaperonin protein TCP-1 alpha and beta subunits showed a significant decrease (P < 0.05) in second trimester brain with DS. Comparable response of chaperone proteins in fetal DS brain suggests that not heat-shock induced proteins but rather chaperonin protein TCP-1 may contribute significantly to neuropathogenesis in the early second trimester DS brain. This study extends observations of distinct expression patterns of molecular chaperones in DS brain and we discuss the relevance of aberrant TCP-1 expression patterns to developmental DS brain at the early stage.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11771755     DOI: 10.1007/978-3-7091-6262-0_27

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  6 in total

Review 1.  Small bowel review: Normal physiology, part 1.

Authors:  Alan B R Thomson; Laurie Drozdowski; Claudiu Iordache; Ben K A Thomson; Severine Vermeire; M Tom Clandinin; Gary Wild
Journal:  Dig Dis Sci       Date:  2003-08       Impact factor: 3.199

2.  Schizophrenia proteomics: biomarkers on the path to laboratory medicine?

Authors:  Shaheen Emmanuel Lakhan
Journal:  Diagn Pathol       Date:  2006-07-17       Impact factor: 2.644

3.  Systematic confirmation study of GWAS-identified genetic variants for Kawasaki disease in a Chinese population.

Authors:  Jiao Lou; Rong Zhong; Na Shen; Xu-zai Lu; Jun-tao Ke; Jia-yu Duan; Yan-qi Qi; Yu-jia Wang; Qing Zhang; Wei Wang; Fang-qi Gong; Xiao-ping Miao
Journal:  Sci Rep       Date:  2015-02-03       Impact factor: 4.379

4.  Inhibition of Raf-MEK-ERK and hypoxia pathways by Phyllanthus prevents metastasis in human lung (A549) cancer cell line.

Authors:  Sau Har Lee; Indu Bala Jaganath; Rishya Manikam; Shamala Devi Sekaran
Journal:  BMC Complement Altern Med       Date:  2013-10-20       Impact factor: 3.659

5.  The TRiC/CCT chaperone is implicated in Alzheimer's disease based on patient GWAS and an RNAi screen in Aβ-expressing Caenorhabditis elegans.

Authors:  Eleonora Khabirova; Aileen Moloney; Stefan J Marciniak; Julie Williams; David A Lomas; Stephen G Oliver; Giorgio Favrin; David B Sattelle; Damian C Crowther
Journal:  PLoS One       Date:  2014-07-31       Impact factor: 3.240

6.  Quantitative proteomic analysis after neuroprotective MyD88 inhibition in the retinal degeneration 10 mouse.

Authors:  Tal Carmy-Bennun; Ciara Myer; Sanjoy K Bhattacharya; Abigail S Hackam
Journal:  J Cell Mol Med       Date:  2021-09-25       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.